Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm is in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates, and formulations. The firm operates one business segment viz. Bulk Drugs and Pharmaceuticals. The company offers three products or services, which includes APIs, Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The company has two manufacturing facilities and one Research Centre. Its API business caters to the needs of the regulated markets, including USA, Europe, Korea, Japan and Latin America. Its research and development (R&D) center is primarily focused on the development and optimization of new and existing process technologies supporting the manufacturing of APIs. Its products under API include Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, Parkinson’s Disease, Hyperparathyroidism, Analgesic (Controlled Substances), and Aromatase Inhibitor.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.